Abbott and Dexcom have reached an agreement to settle all ongoing patent disputes related to their continuous glucose monitoring (CGM) technologies. This resolution ends years of litigation across courts and patent offices worldwide. Both companies, leaders in the CGM market, offer advanced systems: Abbott's FreeStyle Libre 3 and Dexcom's G7.

The settlement includes a 10-year moratorium on patent, trade dress, and design rights disputes between the parties. As part of the agreement, each company granted the other a royalty-free, nonexclusive license to certain patents related to analyte sensing. The settlement involves no financial exchanges, and its details remain confidential.

Abbott emphasized the agreement is a "positive development," enabling the company to focus on advancing diabetes management technologies. Industry analysts noted that this settlement, while significant, was expected given the history of disputes between the two companies.

For more information, please visit Drug Delivery Business.